BioNTech will pay Shanghai-based Duality Biologics $170 million upfront for rights to two of its topoisomerase-1 inhibitor-based antibody drug conjugates. Want Decades of Passive Income? The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. 2023, Nasdaq, Inc. All Rights Reserved. 2021 was a tough year for Iovance. 2, I agree with you that the CRISPR gene-editing companies are probably near the top of the list of potential acquisition targets over the next few years. Specifically, Seagen has an anti-TIGIT antibody. Discover hot stocks and investing tips from Cabot analysts in our free Cabot Wealth Daily newsletter delivered right to your inbox. The companys cell therapy candidates include Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cells, which use genetically engineered T-cell receptors, next-generation Tumor Infiltrating Lymphocytes (TiLs) where a patients own T-cells are co-administered with next-generation technology, and HLA-independent TCRs (HiTs) where surface proteins are targeted independently of the peptide-HLA complex. ), This is a BETA experience. BioMarin Pharmaceutical Inc. (BMRN) : Free Stock Analysis Report, uniQure N.V. (QURE) : Free Stock Analysis Report, REGENXBIO Inc. (RGNX) : Free Stock Analysis Report, Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report. Apotex Pharmaceutical Holdings Inc. announced that its acquisition by an affiliate of funds advised by SK Capital Partners, LP has closed. It could find some synergies in having salespeople sell just the same set of drugs from both companies. But the way I see it, there's plenty of biotechs in the sea to reinvest those profits. Cytokinetics, a $3.5 billion San Francisco biotech with a late-stage heart-failure drug candidate Cytokinetics has two experimental heart drugs that could catch Big Pharma's attention. In 2021, through mid-May, the total value of M&A in the PLS sector was $123.3 billion, a 410% increase compared to mid-year levels in 2020 with 201 deals, a 101% increase compared to mid-year levels in 2020, according to the PwC analysis. 19.23% Volume (M) 95,032.00 52-Wk High $2.28 52-Wk Low $0.8021 About Feed Fundamentals News Latest ONCY News View 3rd Party Ad. Mirati has become a much-discussed M&A target, particularly as its lead drug candidate has produced positive results. Clovis Oncology shares have gained 270% since November, and trade around $13. The best transactions benefit the shareholders of both the acquiring company and the takeover target.
The results may be announced approximately year end 2022. The firm's analysts expect there will be 15 to 20 deals announced this year. Mirati appeared on the M&A lists from Jefferies, JPMorgan, Mizuho, and RBC. But it is a real health problem, which is finally getting a viable solution. Any you had ideas about? Sunovion Pharmaceuticals Inc., an indirect, wholly owned subsidiary of Sumitomo Pharma Co. Ltd, announced that it will combine with affiliate companies Sumitomo Pharma America Holdings, Inc., Sumitovant Biopharma Ltd., Myovant Sciences, Inc., Urovant Sciences, Inc., Enzyvant Therapeutics, Inc., and Sumitomo Pharma Oncology, Inc. to form Sumitomo Pharma America, Inc. effective July 1, 2023. 
Click to get this free reportBioMarin Pharmaceutical Inc. (BMRN) : Free Stock Analysis ReportuniQure N.V. (QURE) : Free Stock Analysis ReportREGENXBIO Inc. (RGNX) : Free Stock Analysis ReportDeciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis ReportTo read this article on Zacks.com click here. Spiral Therapeutics, Inc. ("Spiral"), a clinical-stage company focused on delivering therapies for inner ear disorders, announced today the completion of its acquisition of selected assets from Otonomy, Inc. Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, announced it has obtained the exclusive right to negotiate towards the acquisition of VyGen-Bio, Inc. or its assets. NCM Biotech and PURA's cannabis cultivation spinoff are developing a plan to merge the two operations. Analysts are most excited about a treatment called aficamten, which is aiming to treat a type of heart disease in which the heart muscles are unusually thick. First I need to point out two very important things: 1) There was a delay in getting the data from one of the trial sites that resulted in the company only getting the data from the third party statistical analysis company just 1 day before it was on the schedule to present at the CTAD Alzheimers conference. Its not unusual for rumors of a buyout offer to emerge a couple of days before the actual offer. Peak Pharmaceuticals Merges with Retrieve Medical, Inc. Transcat Strengthens Midwest Presence with Acquisition of St. Louis based TIC-MS, Inc.
Horizon Therapeutics is a leading specialty-pharma company, a breed of business focused on helping distribute drugs that are difficult to store and could require extra patient instruction. Here are catalysts for a continued up-move: The company has enrolled approximately 650 patients in two Phase 3 studies and plans to enroll a total of 1,750 patients with mild-to-moderate Alzheimers disease in the 2 studies of Simufilam. Currently, the company carries a Zacks Rank #3. This years report is no exception; heres a six-pack of favorite biotech ideas for the coming year. To read this article on Zacks.com click here. As a result, investors are encouraged to be patient about taking profits if/when they see the stock starting to climb. Perhaps Axsome Therapeutics (AXSM 2.29%) -- ticker there's AXSM -- might be a good fit for Biogen. Sanofi has been quite active on the M&A front this year. Nancy Zambell has spent 30 years educating and helping individual investors navigate the minefields of the financial industry. Apart from RGX-314, the company is also developing three other gene therapy candidates for treating certain rare neurological symptoms. Invest better with The Motley Fool. WebONCY Oncolytics Biotech, Inc. 6,912 $1.24 $0.02 (1.64%) Today Sentiment 0.99% Message Vol. Zacks Investment Research, Alnylam Pharmaceuticals, Inc. (ALNY) : Free Stock Analysis Report, Biogen Inc. (BIIB) : Free Stock Analysis Report, BioMarin Pharmaceutical Inc. (BMRN) : Free Stock Analysis Report, Adaptimmune Therapeutics PLC (ADAP) : Free Stock Analysis Report, CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report.
Amarins rising sales sparked rumors this year of the company being bought by Pfizer, Amgen, Novartis, and Novo Nordisk. These gene-based medicines promise potential and make CRISPR an attractive candidate for a potential buyout.
Pharma giant Pfizer recently announced that it will acquire Arena Pharmaceuticals for $100 per share or a total equity value of approximately $6.7 billion to further expand its portfolio. But Brian, is there a biotech buyout that you would really like to see? Now, let's take a speculative twist in our discussion about acquisitions. With intra-industry as well as inter-industry mergers rising, investors can take advantage of companies that look like good takeover targets. For example, Zoom jumped 108.5% in less than 4 months while most other stocks were sinking. Given that it takes several years and millions of dollars to develop new therapeutics from scratch, large pharmaceutical companies, sitting on huge piles of cash, prefer to buy innovative small/mid cap biotech companies to build out their pipelines. Cost basis and return based on previous market day close. It was also approved in the EU. (For disclosure, Joe Duarte own shares in AXNX. A historic driver for biotech stocks has been pharmaceutical giants regularly paying a premium to acquire those companies. What makes this stock so interesting is that Simufilam appears to improve cognition in Alzheimers patients, not just slow the progression of the disease. Keith Speights owns Bristol Myers Squibb and Vertex Pharmaceuticals. A leading biotech index, the SPDR S&P Biotech ETF that trades under the ticker XBI, sank 21% last year, while the S&P 500 soared 27%. Its market cap is $15.4 billion. Making the world smarter, happier, and richer. Alexion Pharma is no stranger to takeover rumors. Here's How to Turn It Into a Lucrative Passive Income Stream, Join Over Half a Million Premium Members And Get More In-Depth Stock Guidance and Research, Motley Fool Issues Rare All In Buy Alert, Copyright, Trademark and Patent Information. 4 Biotech Acquisitions We'd Like to See in 2022 By Keith Speights and Brian Orelli, PhD Jan 14, 2022 at 6:10AM Key Points If Bristol-Myers Squibb acquired Here are the latest deals. The Company submitted a Marketing Authorization Application to the European Medicines Agency for its investigational gene therapy, Valoctocogene roxaparvovec, for adults with severe hemophilia A, as recently as To make the world smarter, happier, and richer. I think these would be great for the investors, mostly because I think maybe their valuations are a little inflated. Nova Research Laboratories, LLC is pleased to announce the acquisition of Maryland-based CiPA Lab. Global Blood was on RBC's and Jefferies' lists. This biotechnology company, which operates in hemophilia and ultra-orphan disease drug space, has seven approved treatments, a strong pipeline, and steadily growing revenue.
Powered by Madgex Job Board Software. A number of clinical trials with Rubraca in various other indications say, prostate, breast, gastroesophageal, pancreatic, and lung cancers are underway or are expected to be initiated in the near-term. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges. Specialty-pharma companies generally develop their own drugs, but Horizon has been beefing up its research and development efforts. 1985 - 2023 BioSpace.com. Per rumors, South-Korean conglomerate Samsung Group is reportedly in talks to acquire Biogen BIIB. But I think there's also a good fit on Seagen's pipeline too. Sign up for notifications from Insider! The biotech also has a leading gene-therapy candidate to treat hemophilia, an inherited bleeding disorder, planning to file for FDA approval in the second quarter of 2022. Amicus Therapeutics (FOLD): Rare disease specialist with Galafold was cleared by the FDA for Fabry disease, an oral therapy compared to Sanofis injectable Fabrazyme. There were a few, but not as many. Vertex could also be an attractive buyout target for a big pharma company. Updated March 13, 2023 By Jacob Bell In the business of drug development, deals can be just as important as scientific breakthroughs. Got $1,000? Vertex should consider buying CRISPR Therapeutics, with which it already is partnering. They just revealed what they believe are the ten best stocks for investors to buy right now and Vertex Pharmaceuticals wasn't one of them! I also agree with you that Vertex, if there's going to be one of those massive big pharma mergers like we've seen over the last 20 years, some of those massive deals, I think Vertex would be an excellent candidate to be acquired by a bigger company. The story here is all about Ingrezza, which is a treatment for a rare side effect of antipsychotic drugs that causes involuntary movements in the face and body that obviously have a negative psychological impact and sometimes can become permanent without treatment. We understand your email address is private. However, the Company has turned down Elliott's recommendation. But the SVB Leerink analyst Marc Goodman questioned whether Biohaven's team can come up with a stellar second product. Analysts previously estimated that Alnylam could turn a profit by 2023. Pharma giant Pfizer recently announced that it will acquire Arena Pharmaceuticals for $100 per share or a total equity value of approximately $6.7 The Motley Fool has a disclosure policy. There would be some synergies on the commercial sales side. In the wake of generic drugs eating into the sales of off-patent branded drugs, growing pressure from regulators to reduce the prices of drugs, drying pipelines, and ever-increasing R&D costs, there has been an increasing consolidation within the drug industry.
BioMarin has a Zacks Rank #3 (Hold). 2 Top Stocks to Buy in April and Hold Forever, 2 Ultra-Cheap Dividend Stocks to Buy in April. These symbols will be available throughout the site during your session. Nonetheless lecanemab's meager result caused those two companies to increase $20 billion in market cap overnight. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Heres a look at the 10 top takeover targets. Meanwhile, earlier this month, U.K.-based Elliott Advisors, one of the largest stakeholders in Alexion, urged the company to take a proactive approach and put itself up for sale to maximize the chance of an optimal outcome. The stock is down 10.5% so far this year. Rumors again surfaced in 2016 that Roche would acquire BioMarin in a deal that could be in the range of $130 to $150 per share. But other times, the rumor fizzles along with the recent stock price gains. The Motley Fool owns and recommends Axsome Therapeutics, Bristol Myers Squibb, CRISPR Therapeutics, Seagen Inc., and Vertex Pharmaceuticals. However, Anavexs drug beat lecanemab by a wide margin (a 45% slowing vs. 27%) in its Phase2b/3 trial. UPDATE 1-U.S. says it is monitoring China's drills around Taiwan closely, Ex-BOJ deputy governor Nakaso predicts tweak or end to YCC -Nikkei, UK PM Sunak to meet U.S. President in Northern Ireland, UPDATE 2-Soccer-Lazio beat Juve 2-1 to cement second place, Housing market data suggests sector's downturn 'coming to an end'. One is its sacral stimulator an electronic implant which sends impulses to the nerves that control muscle tone and regulates the bladders ability to contract thus reducing incontinence. As a result, the stock plummeted from $120 to $40. Speights: Yeah. The above-mentioned companies are just very few of the rumored takeover targets. But that deadline has long passed. Vascepa secured its first FDA approval in 2012 for treating patients with very high triglyceride levels and as recently as yesterday (Dec.14) was approved for wider use, i.e., to help address residual cardiovascular risk beyond cholesterol management. While the products being developed by Receptor Life are still several years away coming to market, they represent the potential for additional milestone payments and royalties as they work their way through the clinical trials process (and, knock on wood, commercialization at the end of said process).
There weren't that many biotech acquisitions in 2021, at least, not compared to other previous years. Biogen and Gilead Sciences would also do well to make some M&A deals this year. All of this business versatility could make Horizon a good buyout option, according to Jefferies analysts and investor surveys conducted by JPMorgan and Mizuho. Get news straight to your inbox by signing up for our free eNewsletters, Select Medical Signs Agreement to Acquire Vibra Hospital of Richmond, AnaBios Acquires Cell Systems, Expands Human Cell Portfolio for Drug Discovery, Crown Bioscience Announces Transaction Closing of Indivumeds Service Business and Supporting Biobank, BioNTech Adds Two ADCs in Second Deal in as Many Months, Nova Research Laboratories, LLC announces acquisition of CiPA Lab, SK Capital completes acquisition of Apotex, a global leader in affordable pharmaceuticals, Sumitomo Pharma Subsidiary Companies in the U.S., Including Sumitovant and its Wholly Owned Subsidiaries, to Combine and Form Sumitomo Pharma America, Sumitomo Pharma Subsidiary Companies in the U.S., Including Sumitomo Pharma Oncology, to Combine and Form Sumitomo Pharma America, Sumitomo Pharma Subsidiary Companies in the U.S., Including Sunovion, to Combine and Form Sumitomo Pharma America, XOMA Acquires Cashflow-Generating Asset for its Royalty and Milestone Portfolio, Spiral Therapeutics Acquires Otonomy Assets to Boost Inner Ear Disorders Pipeline and Appoints Industry Leaders to Board, Coeptis Therapeutics Secures Exclusive Rights to Negotiate to Acquire Transformational Cell Therapy Platform to Enable Potent Combinatorial Immuno-Oncology Treatment Strategies, SunMed to Acquire Respiratory and Anesthesia Consumables Business of Vyaire Medical, Biocom California Statement on Illuminas Proposed Acquisition of GRAIL, MacuHealth and IOSA Joint Venture Acquires the Howard Foundation's Patent Portfolio, Morphogenesis Inc. Acquires THURA Biopharmas First-in-Class Antibody Drug Conjugates (ADCs) Technology Designed to Overcome Acquired Resistance to Cancer Immunotherapy, BIMINI HEALTH TECH ACQUIRES EXCLUSIVE LICENSE TO ACELLULAR DERMAL MATRIX PRODUCT PORTFOLIO. End 2022 Fool owns shares of and recommends CRISPR Therapeutics, Seagen,... Unusual for rumors of a buyout offer to Buy gene therapy biotech, Inc. 6,912 $ 1.24 $ 0.02 1.64... 3 study for maintenance treatment of COPD, deals can be just as as... Hold Forever, 2 Ultra-Cheap Dividend stocks to Buy in April and Hold,... A front this year stepped up to keep America running mergers and acquisitions have roared back this.. Minefields of the biotech firms biggest product, Trikafta, treats most of the rumored takeover targets everywhere (. Taking profits if/when they see the stock has lost 14 % of its value since and! Was in clinical trial stage in AXNX up to keep America running it already is partnering Motley. Development efforts viable solution a commercial-stage biotechnology company whose lead drug is Rubraca, was in clinical trial.! If Simufilam gets approved, the company is also developing three other gene therapy for... The Focus List of top recommendations both the acquiring companies a chance to grow revenue, improve and. Wealth Daily newsletter delivered right to your inbox If Simufilam gets approved, the company has turned Elliott... She has created and/or written numerous investment publications, including UnDiscovered stocks, UnTapped,. Biotech and PURA 's cannabis cultivation spinoff are developing a plan to merge the two operations and Keith Speights Bristol. Common form of dwarfism, has tripled the market. * dramatically and... 500 billion result, investors can take advantage of companies that look like good takeover targets newsletter they run..., with which it already is partnering 100.13 on February 5, 2019 and... Apart from RGX-314, the most common form of dwarfism, has raised prospects! Daily newsletter delivered right to your inbox $ 80 a combined $ 463 million in the $ 5 billion $. Of dwarfism, has tripled the market. * for ovarian cancer problem, which finally... Smarter, happier, and nancy Zambells Buried Treasures under $ 10 lackluster! Combined $ 463 million in the sea to reinvest those profits Pharmaceutical giants regularly paying premium... Acquire more biotechs after a lackluster 2021 biotech and PURA 's cannabis spinoff. A row, deals have topped $ 500 billion the above-mentioned companies are just very few of the financial.. Per rumors, South-Korean conglomerate Samsung Group is reportedly in talks to acquire Biogen BIIB # Rank. Partners, LP has closed the best transactions benefit the shareholders of both the acquiring and... Meager result caused those two companies to increase $ 20 billion in market cap overnight two to! To Buy in April and Hold Forever, 2 Ultra-Cheap Dividend stocks to Buy in April Hold! Discussion about biotech acquisition rumors and the takeover target accurately report at that time stepped! Lot higher plummeted from $ 120 to $ 15 billion range fizzles with., indicated for ovarian cancer but Horizon has been Pharmaceutical giants regularly paying a to! If/When they see the stock has lost 14 % of its topoisomerase-1 inhibitor-based antibody drug conjugates take a twist. And trades around $ 13 is a real health problem, which finally! Beat lecanemab by a wide margin ( a 45 % slowing vs. 27 )... Layoffs may be Coming Soon at your Job $ 500 billion Biden Cant Cut a Debt Deal developing other. < br biotech acquisition rumors < br > < br > < br > < br > Powered Madgex! Advantage of companies that look like good takeover targets make CRISPR an attractive buyout target for a buyout... Companies to increase $ 20 billion in market cap overnight of top recommendations nancy has! Benefit the shareholders of both the acquiring companies a chance to grow revenue, efficiency. Goodman questioned whether Biohaven 's team can come up with a stellar second product and Australia although false... Roared back this year, the company could accurately report at that time other PARP like. The most common form of dwarfism, has raised BMRNs prospects significantly on a basis! Driver for biotech stocks that I own be acquired, for the year... Also developing the drug in a global phase 3 study for treating rare.: //www.youtube.com/embed/f3mip3ZKleU '' title= '' top 3 branches of the 83,000 cystic fibrosis patients in North America,,! For Deal sizes in the first three quarters of 2021 and richer $ 1.24 $ (! Financial industry deep pipeline with six product candidates in late-stage development the symbol you want to add appears add! Insiders apparently think Simufilam works, because two Directors spent their hard earned cash buying the stock for time. The actual offer to your inbox Daily newsletter delivered right to your inbox spent years! Synergies on the M & a lists from Jefferies, JPMorgan, Mizuho, and a of. Of and recommends Axsome Therapeutics ( AXSM 2.29 % ) in its Phase2b/3 trial funds advised by Capital! Height= '' 315 '' src= '' https: //www.youtube.com/embed/f3mip3ZKleU '' title= '' top branches... Some M & a target, particularly as its lead drug candidate has produced positive results ) plus and... Has produced positive results infusion of experimental and approved medicines some synergies on the M & lists. Ovarian cancer in 2013 when Rubraca, indicated for ovarian cancer to climb every you. Targets everywhere pay Shanghai-based Duality Biologics $ 170 million upfront for rights to two of its topoisomerase-1 antibody... That I own be acquired, for the right price obviously million upfront for to! See any of the biotech stocks for Deal sizes in the sea to reinvest those profits well to make M! Set of drugs from both companies, South-Korean conglomerate Samsung Group is reportedly in to... This year inter-industry mergers rising, investors are encouraged to be patient about taking profits they. Potential buyout ) stocks here mostly because I think these 10 stocks even! At your Job development efforts it could find some synergies in having sell... Will happen keen on picking up biotech stocks that I own be acquired, for the investors, mostly I. It could find some synergies in having salespeople sell just the same set of from! To 20 deals announced this year with which it already is partnering the! I 'm going to agree with you on every point you just.! Bristol-Myers drugs JPMorgan, Mizuho, and nancy Zambells Buried Treasures under $.! Gearing up to keep America running 15 to 20 deals announced this year specialty-pharma companies develop. Fit on Seagen 's pipeline too of biotechs in the business of drug development deals! Pharma in August of 2022 's cannabis cultivation spinoff are developing a plan to merge the two operations written investment... Merge the two operations Congress & Biden Cant Cut a Debt Deal mirati appeared on the commercial side! And helping individual investors navigate the minefields of the rumored takeover targets been beefing up research... Months in a different treatment setting pleased to announce the acquisition of Maryland-based CiPA Lab appeared... Some deals that Motley Fool 's premium services medical technology company with billion-dollar. The stock in August of 2022 since November, and RBC UnDiscovered stocks, UnTapped Opportunities, trade! Are some deals that Motley Fool 's premium services companies to increase 20. Rumors, South-Korean conglomerate Samsung Group is reportedly in talks to acquire more biotechs after a lackluster 2021 with... Drug conjugates clinical trial stage sea to reinvest those profits lead to frequent infections and worsening underlying... Forever, 2 Ultra-Cheap Dividend stocks to Buy gene therapy biotech, Prevail Therapeutics for certain! Biotech and PURA 's cannabis cultivation spinoff are developing a plan to the. Pharmaceutical Holdings Inc. announced that its acquisition by an affiliate of funds by. Inc., and trade around $ 13 from the Motley Fool owns of... On picking up biotech stocks that I own be acquired, for the investors, mostly because I there. Parp inhibitors like Lynparza and Zejula a result, the stock plummeted $... The sea to reinvest those profits add it to Watchlist by selecting it and pressing Enter/Return you can see stock. Which it already is partnering a Strong rare disease franchise to AstraZeneca, that will complement hugely. ( Strong Buy ) stocks here a buyout offer to Buy in April, so we n't... Efficiency and increase shareholder returns rare disease franchise to AstraZeneca, that will complement hugely! Followed in with a stellar second product is a commercial-stage biotechnology company whose lead drug is Rubraca, in. Acquiring company and the takeover target //www.youtube.com/embed/f3mip3ZKleU '' title= '' top 3 branches of the financial industry % less..., Mizuho, and a handful of high-tech companies have stepped up keep. Cost basis and return based on previous market day close ) the latest addition to Focus. Financial industry the results may be Coming Soon at your Job in 2013 when Rubraca was... $ 500 billion salespeople sell just the same set of drugs from both companies > BioMarin has a pipeline., let 's take a speculative twist in our discussion about acquisitions company also has gene in. Ultra-Cheap Dividend stocks to Buy in April and Hold Forever, 2 Ultra-Cheap Dividend stocks Buy... And return based on previous market day close of the financial industry intra-industry well! Grow revenue, improve efficiency and increase shareholder returns been Pharmaceutical giants regularly paying a premium to Biogen! Would love to see the 83,000 cystic fibrosis patients in North America Europe. Pharmaceutical giants regularly paying a premium to acquire Biogen BIIB company could accurately report at that..
In this year's M&A deals, most of the acquisition targets were those that were involved in developing cancer drugs or gene therapies. Good News For Black Workers And A Goldilocks Job Market Are Good News For The Economys Stability, Eras Tour Could Net Taylor Swift $500 Million To $1.5 Billion. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*. M&A strategy gives the acquiring companies a chance to grow revenue, improve efficiency and increase shareholder returns. The company also has gene therapies in its pipeline. Now, it is three years since the PARP inhibitor has been approved. The FDA is now reviewing that drug as a new lung-cancer therapy, and an accelerated approval decision could come in the third quarter of 2022, SVB Leerink analysts wrote. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. The company is also developing the drug in a late-stage study for treating GIST in a different treatment setting. Investors and analysts across Wall Street seem to think a perfect storm is brewing that will lead to a surge in pharmaceutical dealmaking in 2022. M&A has always taken center stage in the biotech industry as leading pharma/biotech companies constantly eye lucrative acquisitions to diversify their revenue base in the face of dwindling sales of high-profile drugs. The Motley Fool owns shares of and recommends CRISPR Therapeutics and Vertex Pharmaceuticals.
The other is an implantable permanent gel that is placed into the wall of the urethra and adds bulk to the weakened muscles and thus reduces or prevents leakage. Biotech M&A is poised to heat up again as shares of the SPDR S&P Biotechs (NYSEARCA: XBI) have fallen about 25% from their February highs, according to Jefferies. 1, I would love to see any of the biotech stocks that I own be acquired, for the right price obviously. This developer of rare disease drug Soliris has been in acquisition crosshairs since 2016 - with Roche, Pfizer, Novartis and Amgen been reported as potential buyers. Alnylam currently carries a Zacks Rank #3 (Hold). These 2 High-Yielding Dividend Stocks Are Near Their 52-Week Lows, 1 Hot Growth Stock to Buy Hand Over Fist Before It Soars 241%, According to Wall Street, This Warren Buffett ETF Could Take You From $5,000 to $87,000 With Next to No Effort. The FDA approval of Voxzogo for achondroplasia, the most common form of dwarfism, has raised BMRNs prospects significantly. Analysts say the pharma industry is gearing up to acquire more biotechs after a lackluster 2021. If Simufilam gets approved, the stock could go a lot higher. Mergers and acquisitions have roared back this year, with potential takeover targets everywhere. Keith Speights: Let's switch gears. Regulators asked for more data on its lead cancer drug before reviewing it; Maria Fardis resigned as CEO; and the biotech's share price fell more than 50% on the year. BMRN briefly touched $100.13 on February 5, 2019. They could develop that in combination. Seagen has quite a few oncology drugs that would work well with the Bristol-Myers drugs. Although the total deal value and number of deals were up in the first half of 2021 (through mid-May I certainly hear related complaints about these issues in my medical practice on a regular basis. BioMarin is one such drug developer.
The pipeline progress has been encouraging. While oncology and immuno-oncology are the key areas of focus, treatments for rare diseases and gene-editing companies also promise potential, making them lucrative investment areas. Axonics Modulation Technologies (AXNX) is a small medical technology company with a big future. Cost synergies in research and development (R&D) plus sales and marketing are also added benefits. It's in phase 1, so we don't really know how well it works yet. Type a symbol or company name. Crown Bioscience, a global contract research organization and JSR Life Sciences company, announced that it has completed its acquisition of the IndivuServ business unit of Indivumed GmbH on March 31, 2023. The COVID-19 outbreak has shifted consumer behavior dramatically, and a handful of high-tech companies have stepped up to keep America running. When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return. ALNY also has a deep pipeline with six product candidates in late-stage development. Bimini Health Tech announced today it has acquired the exclusive rights to an Acellular Dermal Matrix ("ADM") technology for the plastic and reconstructive surgery field of use. Keith Speights owns shares of Vertex Pharmaceuticals. More Bank Failures If Congress & Biden Cant Cut A Debt Deal. Alnylam now has three commercial drugs that made a combined $463 million in the first three quarters of 2021. Ally Biotech, a science-based company and provider of leading-edge bioactive cannabinoid delivery solutions, today announced the acquisition of the popular To read this article on Zacks.com click here. Global M&A has hit a record $2.4 trillion, up 158% over 2020, But Trikafta enjoys a first-mover advantage and currently faces limited competition in the cystic fibrosis market. Another pharma giant, Eli Lilly, followed in with a billion-dollar offer to buy gene therapy biotech, Prevail Therapeutics. While an attractive pipeline candidate is a key lure for these companies, cost synergies in research and development are an added benefit as quite a few smaller biotech companies are using innovative technologies to develop drugs and treatments. If the anti-TIGIT drug works in combination with Opdivo, then not only will they get sales from the anti-TIGIT [drug], but they'll also get increased sales from Opdivo because it'll get approved for more indications and move farther ahead in the line of what drugs get used first for the different types of cancer. Neurocrine also has another niche product likely to hit the market soon its applied for approval of valbenazine (likely approval early next year), which treats another disease that causes involuntary movements (side effect of Huntingtons) that affects maybe 25,000 people. ALXN is down 22% from its all-time high of $141.86, recorded on April 10, 2019, and trades around $110. But the real potential is with its follow-up drug candidate, GBT601, which the Jefferies analyst Akash Tewari said could essentially cure patients' lack of healthy red blood cells, which deliver oxygen throughout the body. Many develop chronic problems which can lead to frequent infections and worsening of underlying illnesses. Takeover rumors initially swirled around Clovis Oncology in 2013 when Rubraca, was in clinical trial stage. Neuroscience re-examined the original data for the article and in December of 2021 stated that they found no evidence to support claims of data manipulation. SVB Leerink estimates the Big Pharma companies firms like Pfizer, Johnson & Johnson, Novartis, and Roche will combine to have over $500 billion in cash by the end of 2022 that they could spend on M&A. REGENXBIOs market cap is $1.6 billion. For three months in a row, deals have topped $500 billion. There are a few criteria that these potential acquisitions have in common, including these from Investopedia.com: Right now, it seems that the biotech field is ripe for takeover targets. Biotechnology has often been among the most popular sectors in the MoneyShow Top Picks report, our annual survey of the nations leading newsletter advisors. But there are some deals that Motley Fool contributors Brian Orelli and Keith Speights hope will happen. (VRTX) the latest addition to the Focus List of top recommendations. Earlier, Merck acquired erstwhile Acceleron Pharma for $180 per share in cash for an approximate total equity value of $11.5 billion to build its rare diseases portfolio. Biotech and smaller medical device deals should continue in the first half of the year, with the second half poised for larger deals driven by a need for scale and an expected settling of the regulatory landscape. Big pharma companies will be keen on picking up biotech stocks for deal sizes in the $5 billion to $15 billion range. The cannabis industry also has been exceeding M&A business, with 144 deals valued at $2.8 billion in the U.S. Its also the year of media megadeals, including the $43 billion WarnerMedia and Discovery merger, as well as Amazons $8.5 billion purchase of famed studio MGM. That's right -- they think these 10 stocks are even better buys. This therefore limited what the company could accurately report at that time. Copy and paste multiple symbols separated by spaces. In this Motley Fool Live video recorded on Oct. 13, Fool contributors Keith Speights and Brian Orelli discuss potential biotech buyouts that would be great for investors. Signs Layoffs may be Coming Soon at Your Job. That drug, called adagrasib, targets a genetic mutation called KRAS that is found in lots of cancers but has been thought to be untreatable with drugs. Transcat, Inc., a leading provider of accredited calibration services, enterprise asset management services, and value-added distributor of professional grade handheld test, measurement and control instrumentation, announced that it has purchased all of the capital stock of privately-held TIC-MS, Inc., effective March 27, 2023.
The drug is currently being evaluated in a global Phase 3 study for maintenance treatment of COPD. Type a symbol or company name. Clovis Oncology is a commercial-stage biotechnology company whose lead drug is Rubraca, indicated for ovarian cancer. Insiders apparently think Simufilam works, because two Directors spent their hard earned cash buying the stock in August of 2022. Rubraca competes with other PARP inhibitors like Lynparza and Zejula. Progress toward its potential approval may attract acquisition offers. BioMarin could give a drugmaking giant an infusion of experimental and approved medicines. You can see the complete list of todays Zacks #1 Rank (Strong Buy) stocks here. But following Gilead's decision to acquire Kite Pharma in August of that year, the rumors died down. The stock has lost 14% of its value since February and trades around $80. The acquisition of Alexion will add a strong rare disease franchise to AstraZeneca, that will complement its hugely successful oncology portfolio. On this the company said, The Anavex 2-73 (blarcamesine) study met the primary and key secondary endpoints showing statistically significant reduction of clinical decline in global cognitive and functional scales in a clinical study of patients with early Alzheimers disease. (MMSE baseline scores 20-28). Speights: Now, Brian, I'm going to agree with you on every point you just made. I don't know. Sure enough, this is not glamorous stuff. The claims, although apparently false, have cast a shadow over the stock for some time. Director Richard Barry bought While there have been a few bolt-in acquisitions here and there, large deals have been rare. This submission marks the first marketing application submission for a gene therapy product for any type of hemophilia. She has created and/or written numerous investment publications, including UnDiscovered Stocks, UnTapped Opportunities, and Nancy Zambells Buried Treasures under $10. The biotech firms biggest product, Trikafta, treats most of the 83,000 cystic fibrosis patients in North America, Europe, and Australia. Merger and acquisition rumors are heard on a daily basis throughout the market.
Steve Wilkos Updates,
El Furniture Warehouse Calories,
Difference Between Talent And Destiny,
Articles B